New details have emerged about an initiative that starts in December to fast-track the vaccines, similar to the successful ...

<?xml encoding="utf-8" ?> A nationwide initiative to accelerate personalized cancer vaccine development is drawing fresh ...

Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine ...

Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a ...

Moderna stock gains on reports of an initiative to accelerate cancer vaccine development. Here’s why caution is warranted in ...

The National Institutes of Health plans to launch a public-private partnership in December to speed development of personalized cancer vaccines, according ...

Add Yahoo as a preferred source to see more of our stories on Google. Moderna and Merck's mRNA cancer vaccine, combined with the latter's immunotherapy medication Keytruda, showed promise in ...

Moderna (MRNA) stock surged 14% after reports of a new NIH cancer research initiative and encouraging trial data with Merck.

The personalized mRNA shot teaches the body to attack a patient’s specific melanoma cells A new vaccine could soon protect patients from returning skin cancer. In a large clinical trial, patients with ...

Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & Early Translational ...

In the early 2000s, immunologist Bali Pulendran started his lab at Emory University to explore the mechanisms underlying vaccine-mediated immunity. To uncover these processes, he focused on the yellow ...

Four pathogens account for most infection-related cancers, a new study highlights, but the tools to prevent them range from ...